Business Context and Reporting Period
This Form 8-K Current Report from Becton, Dickinson and Company (BD) covers events occurring on April 24, 2015, with the report filed on April 29, 2015. The filing details the completion of debt exchange offers related to senior notes originally issued by CareFusion Corporation, a wholly owned subsidiary of BD.
Key Financial Metrics and Debt Structure
The filing focuses on the restructuring of debt obligations rather than operational financial metrics such as revenue or cash flow. The following debt exchange transactions were executed:
- Old Notes Cancelled (CareFusion): Approximately $1.95 billion in aggregate principal amount of CareFusion Senior Notes were tendered and cancelled.
- New Notes Issued (BD): BD issued new Senior Notes with an aggregate principal amount of approximately $1.95 billion to replace the cancelled CareFusion notes.
- Remaining Outstanding CareFusion Notes: Approximately $50.85 million in CareFusion Notes remain outstanding across five series.
Specific breakdown of the exchange:
| Note Series | Old Notes Cancelled | New Notes Issued |
|---|---|---|
| 1.450% due 2017 | $292,928,000 | $292,899,000 |
| 6.375% due 2019 | $665,002,000 | $664,855,000 |
| 3.300% due 2023 | $293,850,000 | $293,850,000 |
| 3.875% due 2024 | $397,492,000 | $397,441,000 |
| 4.875% due 2044 | $299,877,000 | $299,877,000 |
The filing text does not provide values for revenue, profit, operating cash flow, margins, or overall liquidity positions.
Material Changes Versus Prior Period
The primary material change is the shift in the obligor of the debt from the subsidiary (CareFusion Corporation) to the parent company (Becton, Dickinson and Company). Additionally, the indentures for the remaining outstanding CareFusion Notes were amended to:
- Eliminate substantially all restrictive covenants.
- Eliminate cross-default provisions under CareFusion's indebtedness.
- Permit BD's periodic reports to satisfy reporting covenants.
Guidance, Outlook, and Risks
The filing does not contain management commentary on future business outlook, revenue guidance, or earnings projections. However, it outlines specific risks and terms associated with the new debt instruments:
- Redemption Rights: BD may redeem the 2017 and 2019 Notes at any time prior to maturity. The 2023, 2024, and 2044 Notes may be redeemed prior to specific dates (Dec 1, 2022; Feb 15, 2024; Nov 15, 2043) at a premium, or at 100% of principal thereafter.
- Change of Control: Holders have the right to require BD to purchase the Notes at 101% of principal plus accrued interest upon a Change of Control Triggering Event.
- Events of Default: Include failure to pay interest or principal, failure to perform covenants for 60 days after notice, and bankruptcy/insolvency events.
Key Facts for Investor Verification
- Verify the exact amount of remaining CareFusion debt ($50.85 million) and its current covenant status.
- Confirm the interest rate and maturity dates of the new BD-issued notes to assess future interest expense.
- Review the "Fourth Supplemental Indenture" (Exhibit 4.1) for the full scope of covenant eliminations on remaining subsidiary debt.
- Monitor BD's ability to service the new debt obligations, particularly the 6.375% Notes due 2019 which carry the highest coupon rate among the exchanged series.